SOURCE: Naviscan


June 12, 2012 09:00 ET

Cutting Edge Naviscan PEM Research Presented at SNM 2012

Studies Focused on Novel Radiotracers, New Applications and Clinical Validation of Low-Dose Positron Emission Mammography

MIAMI, FL--(Marketwire - Jun 12, 2012) - Several groundbreaking studies on the Naviscan PET scanner, the breast application for which is Positron Emission Mammography (PEM), were presented this week at the Annual Meeting of the Society of Nuclear Medicine (SNM) in Miami, Florida. Researchers from the Johns Hopkins University, Thomas Jefferson University, Boston University and University of Washington presented abstracts focusing on use of novel radiotracers, new clinical applications as well as low-dose imaging with PEM.

Dr. Mathew Thakur from Thomas Jefferson University presented results of an ongoing head-to-head comparison of 18F-FDG with a novel low-dose radiotracer Cu-64-TP3805 (NuView Life Sciences, Park City, UT) demonstrating concordance. This is significant since the dose from Cu-64 is similar to one mammogram and does not require fasting indicating a potential for PEM to be used in a screening capacity. Dr. Richard Wahl of Johns Hopkins University presented results on feasibility of using the technology for metabolic assessment and evaluation of treatment response for patients with osteoarthritis. Drs. Gustavo Mercier from Boston University and Lawrence MacDonald from University of Washington shared clinical and research validations of performing PEM imaging using 50% less radiation.

"The future of diagnostic imaging will be dependent on the optimization of molecular imaging technologies and novel, targeted radiotracers," stated Paul Mirabella, Chairman and CEO of Naviscan. "The goal of this research is to minimize dose without compromising the best possible diagnostic information. The ground breaking work of these world renowned researchers is a significant step forward in the quest for such optimization."

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity." Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI), device on the market with biopsy-guidance.

About Naviscan, Inc.

Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the world with global distribution in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.

Contact Information

  • Contact Information
    Guillaume Bailliard
    Executive Vice President
    Naviscan, Inc.
    Tel: +1.858.332.0941
    Email Contact

    Joleen Schultz
    Naviscan Marketing Communications
    321 Medical Launch
    Tel: +1.858.455.5500
    Email Contact